1. Market Research
  2. > Pharmaceutical Market Trends
  3. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Turkey

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Turkey
TURKEY 1
HEALTHCARE SYSTEM1
Facts and Figures1
Market Indicators2
Provision and Funding4
Universal Health Insurance Scheme4
Private Health Insurance 5
Regulation, Funding and Provision6
Syrian Refugee Crisis7
PRICING7
Prescription Drugs7
Applications8
Price Evaluation Commission8
International Reference Pricing9
Mandatory Discounts12
Generic Drugs13
Price Caps13
Mandatory Manufacturer Discounts14
Internal Reference Pricing14
Hospital Drugs14
Special Pricing Provisions14
Actual Prices15
OTC Drugs 15
REIMBURSEMENT16
Admission to Reimbursement16
Assessment Process17
Reimbursement Restrictions18
Timelines 18
Reimbursement Categories19
Reimbursement Prices 19
Mandatory Discounts19
Internal Reference Price System21
Hospital Reimbursement21
Formularies21
Funding21
Changes in Reimbursement Status22
Changes in Reimbursement Prices22
Price Adjustments22
PHARMACOECONOMICS24
Pharmacoeconomic Requirements24
PRICE BUILD UP26
Wholesalers26
Margins26
Background26
Retail Pharmacies26
Margins27
Other Fees27
Mandatory Discounts 27
Regulations28
Hospital Drugs29
Dispensing Doctors29
Sales Tax29
COST CONTAINMENT30
Industry Paybacks30
Promotional Costs 30
Patient Co-payments31
Pharmaceuticals31
Healthcare32
Prescribing Controls 32
Electronic Prescriptions33
Monitoring of Prescriptions33
Treatment Guidelines33
Prescribing Restrictions33
Generics 34
Intellectual Property34
Rx-to-OTC Switches35
Parallel Trade35
Supply Shortages 35
Access to Imported Products35
FUTURE DEVELOPMENTS37
Outlook 37
Pricing and Reimbursement Reforms37
Alternative Reimbursement Commission39
New SGK/TEB Service Agreement40
NAMES and ADDRESSES41

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.